Comparison · NCT00688740-e3f8f024
TAC (Docetaxel) vs FAC (5-fluorouracil): Number of Participants With Second Primary Malignancies (Toxicity)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TAC (Docetaxel) vs FAC (5-fluorouracil): Number of Participants With Second Primary Malignancies (Toxicity). Trial comparisons, record NCT00688740-e3f8f024. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00688740-e3f8f024
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0899 | 0.0714 | 0.113 | wilson | |
| Risk in group 2 | 0.0885 | 0.0701 | 0.111 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00146 | -0.0277 | 0.0306 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.735 | 1.41 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.713 | 1.45 | log | |
| Number needed to treat, for one more participant with the outcome on TAC (Docetaxel) than on FAC (5-fluorouracil) | 684 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TAC (Docetaxel) | docetaxel in combination with doxorubicin and cyclophosphamide | 67 | 745 | OG000 |
| Group 2 | FAC (5-fluorouracil) | 5-fluorouracil in combination with doxorubicin and cyclophosphamide | 66 | 746 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Second Primary Malignancies (Toxicity)
- Description
- Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.
- Time frame
- up to 10 year follow-up
- Population
Source ClinicalTrials.gov
Trial
- Title
- Docetaxel in Node Positive Adjuvant Breast Cancer
- NCT number
- NCT00688740
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- Docetaxel, 5-fluorouracil, Doxorubicin, Cyclophosphamide
- Lead sponsor
- Sanofi
- Results first posted
- 2011-02-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00688740?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00688740-e3f8f024